Antibodies to sulfated glycolipids in Guillain-Barré syndrome

TY - JOUR

T1 - Antibodies to sulfated glycolipids in Guillain-Barré syndrome

AU - Illyas, Amjad A.

AU - Mithen, Francis A.

AU - Dalakas, Marinos C.

AU - Wargo, Michelle

AU - Chen, Zi Wei

AU - Bielory, Leonard

AU - Cook, Stuart D.

N1 - Funding Information: This work was supported by National Multiple Sclerosis Society Grants RG2064-A-1 (A.A.I.) and RG1636-A-1 (F.A.M.), Lions Eye Research Foundation of New Jersey (L.B.) and by the Department of Veterans Affairs (F.A.M.). The authors thank Jean Chou, Biostatistician at ACS, UMDNJ, for performing the statistical analysis.

PY - 1991/9

Y1 - 1991/9

N2 - Sera from 53 patients with acute Guillain-Barré syndrome (GBS), 15 patients with chronic inflammatory demyelinating polyneuropathy (CIDP), 13 patients with other neurological diseases (OND) and 31 healthy controls were tested for IgM and IgG antibodies to sulfoglucuronyl paragloboside (SGPG) and sulfatide by both an ELISA and a thin-layer chromatogram-overlay technique. Although the mean levels of anti-SGPG or anti-sulfatide antibodies in GBS patients were not elevated compared to controls, the occurrence of anti-SGPG antibodies was more frequent in GBS patients than in controls (P < 0.02). Acute GBS patients with antibodies to SGPG or sulfatide were clinically indistinguishable from other GBS patients. Our data suggest that elevated levels of antibodies to SGPG could be important in the pathogenesis of neuropathy in some GBS patients.

AB - Sera from 53 patients with acute Guillain-Barré syndrome (GBS), 15 patients with chronic inflammatory demyelinating polyneuropathy (CIDP), 13 patients with other neurological diseases (OND) and 31 healthy controls were tested for IgM and IgG antibodies to sulfoglucuronyl paragloboside (SGPG) and sulfatide by both an ELISA and a thin-layer chromatogram-overlay technique. Although the mean levels of anti-SGPG or anti-sulfatide antibodies in GBS patients were not elevated compared to controls, the occurrence of anti-SGPG antibodies was more frequent in GBS patients than in controls (P < 0.02). Acute GBS patients with antibodies to SGPG or sulfatide were clinically indistinguishable from other GBS patients. Our data suggest that elevated levels of antibodies to SGPG could be important in the pathogenesis of neuropathy in some GBS patients.

KW - Guillain-Barré syndrome

KW - Immunoglobulins

KW - Myelin-associated glycoprotein

KW - Sulfatide

KW - Sulfoglucuronyl glycolipids

UR - http://www.scopus.com/inward/record.url?scp=0025848459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025848459&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/0022-510X(91)90126-R

DO - https://doi.org/10.1016/0022-510X(91)90126-R

M3 - Article

C2 - 1795163

VL - 105

SP - 108

EP - 117

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1

ER -